Ann: Trading Halt, page-262

Did you even read the conclusions of this PHASE 2 study on Sprifermin that your link referred to:

"Conclusions and relevance: Among participants with symptomatic radiographic knee osteoarthritis, the intra-articular administration of 100 μg of sprifermin every 6 or 12 months vs placebo resulted in an improvement in total femorotibial joint cartilage thickness after 2 years that was statistically significant, but of uncertain clinical importance; there was no significant difference for 30 μg of sprifermin every 6 or 12 months vs placebo. Durability of response also was uncertain."

Hardly seem like "competition" based on this study, if you have read any actual detail on the Paradigm PHASE 2 results.